Amber Gibson

Amber Gibson is a physician-scientist at The University of Texas MD Anderson Cancer Center specializing in pediatric hematology and oncology. Her research focuses on hematological malignancies, particularly acute leukemias and lymphomas, with emphasis on immunotherapy combinations, targeted therapies, and post-transplant maintenance strategies. Her recent work includes investigating menin inhibition-related differentiation syndrome, immune-related toxicities following hematopoietic stem cell transplantation with rituximab, inotuzumab, and blinatumomab, and novel treatments for relapsed/refractory ALK-positive ALCL. She has also studied early death risk among adolescents and young adults with acute leukemia and asparaginase-associated hypertriglyceridemia. Her publications appear in Blood Advances, British Journal of Haematology, and JNCI Cancer Spectrum.